ATPase family AAA domain containing 2BGenealiases: []
Q-omics provides the consensus-scored ATAD2B profile across patient tissues and cancer cell-line models. ATAD2B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ATAD2B is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ATAD2B protein abundance shows 25,740 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where ATAD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATAD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATAD2B survival associations across molecular data types. ATAD2B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATAD2B RNA expression–survival associations across cancer types. High ATAD2B expression shows unfavorable associations in ACC, KIRP, MESO and UVM, but favorable associations in HNSC and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ATAD2B RNA expression.
This table summarizes ATAD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ATAD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATAD2B shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LUSC, STAD and BRCA. The BLCA box plot shows higher ATAD2B RNA expression in tumor versus normal tissue (log2 FC = +0.717, t-test p < 0.001).
This table shows molecular features associated with ATAD2B in patient tissues and cancer cell lines. In patient samples, ATAD2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATAD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
